HOME >> BIOLOGY >> NEWS
From gene discovery to preventing eye disease in retinitis pigmentosa

but has a characteristically slowed recovery time in the dark. Decline of vision is gradual. Naturally occurring rhodopsin mutant dogs that we studied mimic the latter type of human disease."

Cideciyan and colleagues Samuel G. Jacobson, MD, PhD, the F.M. Kirby Professor in Penn's Department of Ophthalmology and Director of the Center for Hereditary Retinal Degenerations at Scheie, Gustavo D. Aguirre, VMD, PhD, Professor of Medical Genetics and Ophthalmology at Penn's School of Veterinary Medicine, and Gregory M. Acland, BVSc, of Cornell University asked whether modest light levels cause damage to retinas of the rhodopsin mutant dogs. The investigators performed the routine clinical procedure of retinal photography in the dogs. Normal dogs had no ill effects of the procedure. Surprisingly, the mutant dogs had complete degeneration one month after retinal photography and only in those regions that were photographed. There were no abnormalities associated with neighboring regions of the retina that were not photographed. Further experiments with focal light exposures and cross-sectional retinal imaging showed that retinal injury was detectable within 30 minutes and could cause complete retinal degeneration within a month following these moderate lights.

"Rhodopsin mutant dogs are one of several naturally occurring canine retinal degenerations which duplicate human hereditary eye diseases," comment Aguirre and Acland, who have spent more than 20 years identifying and investigating inherited veterinary retinal degenerations and their treatments. "Identifying a light-induced component to the natural history of retinal degeneration in the rhodopsin mutant dogs means that now we can test new treatments for value and safety before attempting the same in human patients."

When the investigators used lower light exposure levels, the degeneration process was slower and lasted six months or longer. Even further lowering of light exposure resulted in reti
'"/>

Contact: Olivia Fermano
olivia.fermano@uphs.upenn.edu
215-349-5653
University of Pennsylvania School of Medicine
22-Mar-2005


Page: 1 2 3

Related biology news :

1. Enzyme discovery sheds light on vitamin D
2. New proteomics research promises to revolutionize biomedical discovery
3. MU researchers make discovery in molecular mechanics of phototropism
4. International team to honor 30th anniversary of deep-sea vent discovery in Galpagos
5. Screening approach leads to discovery of gene linked to breast cancer
6. Lucky 13 as new gene discovery offers further hope for childhood blindness
7. Plants that produce more vitamin C may result from UCLA-Dartmouth discovery
8. Biting discovery: MU entomologist finds host of new aquatic insect species in Thailand
9. J&JPRD discovery may lead to new treatments for chronic sensitivity, pain caused by cold
10. Protein enables discovery of quantum effect in photosynthesis
11. Unicellular microRNA discovery

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/20/2017)... ALLENTOWN, Pa. , March 20, 2017 ... PD 2.0 personal spirometer and Wellness Management System (WMS), ... Founded in 2010, PMD Healthcare is a ... Company with a mission dedicated to creating innovative solutions ... of life. With that intent focus, PMD developed the ...
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, 2017 /PRNewswire/ ... 23andMe , the leading personal genetics company, are ... can now provide customers with personalized nutrition plans that ... biometrics, but also genetic markers impacting how their body ... personalized food decision support platform uses biometrics such as ...
(Date:3/2/2017)... -- Summary This report provides all the information ... and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... provides an in-depth insight into the partnering activity of one ... demand company reports are prepared upon purchase to ensure inclusion ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... , March 22, 2017 Oramed Pharmaceuticals ... www.oramed.com ), a clinical-stage ... drug delivery systems, announced today that Dr. ... deliver a presentation titled, "Oral Insulin for Diabetes ... Cambridge Healthtech Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference ...
(Date:3/22/2017)... ALBANY, New York , March 22, 2017 /PRNewswire/ ... market is largely fragmented, states a research report by ... Sanofi S.A., Pfizer Inc., Amgen Inc., and AbbVie Inc., ... market in 2015. The prominent players in this market ... to expand their product portfolio, which is likely to ...
(Date:3/22/2017)... , March 22, 2017 /PRNewswire/ - FACIT announced ... "Company" or "Propellon"), a start-up created by FACIT ... therapeutics. FACIT,s investment, combined with non-dilutive capital, achieves ... The seed funding enables Propellon to accelerate the ... Company for financing and/or entering a strategic partnership ...
(Date:3/22/2017)... 2017   VWR (NASDAQ: VWR), ... and service solutions to laboratory and production ... EPL Archives, Inc., an international biorepository services ... regulated product research, development and commercialization lifecycle ... ancillary services. EPL Archives is widely recognized ...
Breaking Biology Technology:
Cached News: